Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18556116 | 0.79 | OPRM1 (0.40) | L3MBTL1L3MBTL3OPRM1OPRK1OPRL1 | |
| SCHEMBL22660642 | 0.76 | ALDH1A1 (0.40) | FAAHMGLLMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4954604 | 0.76 | ALDH1A1 (0.38) | L3MBTL1L3MBTL3OPRM1OPRK1OPRL1 | |
| SCHEMBL28949648 | 0.74 | NPC1 (0.42) | L3MBTL1FAAHMGLLSMN1; SMN2ALDH1A1 | |
| SCHEMBL4956153 | 0.73 | CYP19A1 (0.42) | L3MBTL1L3MBTL3CYP19A1FAAHMGLL | |
| SCHEMBL22660700 | 0.72 | ACKR3 (0.43) | MEN1KMT2ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL9293015 | 0.72 | CYP19A1 (0.51) | L3MBTL1L3MBTL3CYP19A1FAAHMGLL | |
| SCHEMBL22666670 | 0.71 | OPRD1 (0.44) | MEN1KMT2ASMN1; SMN2CCR5CYP2D6 | |
| SCHEMBL24290451 | 0.71 | FAAH (0.41) | L3MBTL1FAAHMGLLSMN1; SMN2TP53 | |
| SCHEMBL9293306 | 0.69 | CYP19A1 (0.51) | L3MBTL1L3MBTL3CYP19A1FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015146-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-01-17 | — | — | US | disclosed |
| CN-101006083-A | Dpp-iv inhibitor | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-25 | — | — | CN | disclosed |
| EP-1786806-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121131-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015146-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP3 | L3MBTL1 2585/4885L3MBTL3 3088/4885CYP19A1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.